Ras (G12D Mutant Specific) Recombinant Rabbit mAb (S-5958)

The KRAS G12D mutant-specific designation refers to a class of therapeutic agents designed to selectively target the glycine-to-aspartate substitution at codon 12 of the KRAS oncoprotein, which is the most prevalent KRAS mutation in human cancers, occurring in approximately 40% of pancreatic ductal adenocarcinomas, 15% of colorectal cancers, and 5% of lung cancers. Unlike the G12C mutant, which possesses a reactive cysteine residue amenable to covalent inhibition, the G12D mutant lacks such a handle and has historically been considered "undruggable," necessitating the development of non-covalent inhibitors that exploit the mutant aspartate for selectivity. A landmark achievement in this field is MRTX1133, a potent, non-covalent inhibitor that binds the Switch II pocket with picomolar affinity (Kd ~0.2 pM for GDP-bound KRAS G12D) and exhibits ~700-fold selectivity over wild-type KRAS by forming key electrostatic interactions—including a salt bridge—with the Asp12 side chain. Mechanistically, MRTX1133 "freezes" the nucleotide-binding site conformation, arresting the GTPase cycle in both GDP- and GTP-bound states and attenuating downstream ERK phosphorylation and tumor growth in preclinical models. Beyond MRTX1133, several other G12D-selective agents are advancing through development, including VS-7375 (GFH375), an oral dual ON/OFF inhibitor with picomolar affinity and sustained pathway inhibition compared to ON-only inhibitors; RNK08954, which has demonstrated an unconfirmed objective response rate of 58.33% in NSCLC patients in early-phase trials; and setidegrasib (ASP3082), a first-in-class PROTAC degrader targeting KRAS G12D. In the clinical context, KRAS G12D-mutant tumors exhibit a propensity to activate the PI3K/AKT pathway and foster an immunosuppressive microenvironment, and emerging evidence suggests that resistance to G12D-selective inhibitors involves autophagy-mediated glutathione synthesis and a shift toward histone acetylation that can be overcome by BET inhibition, informing rational combination strategies.